Funding news · Nov 19, 2026

IntelliProve Raises €2.7M Seed Led by Miles Ahead for Facial Biomarker Tech

IntelliProve, a Belgium-based health tech startup, has raised a €2.7 million Seed round led by Miles Ahead. The round was disclosed on November 19, 2026, and includes participation from Wit-Gele Kruis and imec.istart.

What IntelliProve Does

IntelliProve develops software that uses optical facial measurements to determine physiological and mental health parameters. The technology captures a 20-second video of a user's face, then applies AI and signal processing to analyze blood flow and other vital indicators.

The output is real-time, clinically validated biomarker data intended for integration into healthcare platforms and applications. Rather than selling a standalone consumer app, the company positions its technology as a component that other healthcare platforms can embed.

Commercial Footprint

IntelliProve serves clients in Belgium, the Netherlands and the United Kingdom. This gives the company a base in three European markets, with the UK providing a non-EU regulatory and commercial environment alongside its Benelux home base.

Round Details

  • Round type: Seed
  • Amount: €2.7 million
  • Lead investor: Miles Ahead
  • Other investors: Wit-Gele Kruis, imec.istart
  • Funding date: November 19, 2026
  • Currency: EUR

Why It Matters for Acquisition

IntelliProve operates at the intersection of computer vision, signal processing and clinical validation, a combination that is difficult to assemble and slow to certify. The company's stated emphasis on clinically validated biomarkers is the key differentiator to scrutinize: validation claims, the scope of regulatory clearances and the evidence base behind them will determine how readily the technology can be embedded in regulated healthcare workflows.

The integration-first model is relevant for acquirers. A component that plugs into existing healthcare platforms can be absorbed by telehealth providers, remote patient monitoring vendors, electronic health record integrators or insurers building wellness and risk-assessment products. The 20-second capture format lowers friction for end users, which matters for adoption at scale.

Investor composition offers signals about the company's trajectory. imec.istart is associated with the Belgian nanotechnology research ecosystem, suggesting proximity to deep technical talent and validation infrastructure. Wit-Gele Kruis, a home care organization, points to a care-delivery channel rather than purely financial backing. Miles Ahead led the round.

Key diligence areas for potential acquirers include the depth of clinical validation across the specific parameters measured, reimbursement pathways in Belgium, the Netherlands and the UK, data privacy and biometric data handling obligations under European regulation, and the concentration of the current client base across three markets.

Summary

IntelliProve has raised €2.7 million in Seed funding led by Miles Ahead, with Wit-Gele Kruis and imec.istart participating, disclosed November 19, 2026. The company's software derives physiological and mental health parameters from a 20-second facial video using AI and signal processing, delivering real-time clinically validated biomarker data for integration into healthcare platforms. It serves clients in Belgium, the Netherlands and the United Kingdom.

© 2026 VeilStrat. All rights reserved.All systems operational